Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease
Authors' conclusion
U-β2M is a promising, non-invasive prognostic and treatment-associated marker for MDA5-DM with ILD, showing more pronounced longitudinal change than serum ferritin and KL-6. However, given the retrospective, single-center design of this study, prospective validation in larger cohorts is warranted.
Study context
- Population
- Patients with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM) with interstitial lung disease (ILD) admitted between January 2004 and March 2023baseline U-β2M available (16 deaths, 36 survivors), 63 patients included (20 deaths, 43 survivors) of 68 identified · included 63 · baseline U-β2M available 52
- Participants
- 52 patientsEvents: 16
- Predictors
- Urinary β2-microglobulin (U-β2M); serum ferritin, anti-MDA5 antibody titres and serum Krebs von den Lungen-6 (KL-6) compared
- Predicted outcome
- mortality
Model performance
As reported in the abstract
Area under the curve
U-β2M
0.72
Serum ferritin
0.68
anti-MDA5 antibody titres
0.69
KL-6
0.50
- U-β2M comparable to serum ferritin and anti-MDA5 antibody titres
- U-β2M vs KL-6: P = 0.0394
Further findings
U-β2M levels at admission, deceased vs survivors
- Significantly higher in the deceased group
- P = 0.011
Correlation of U-β2M with anti-MDA5 antibody titres and serum ferritin
- Correlation with anti-MDA5 antibody titres
- P < 0.0001
- Correlation with serum ferritin
- P < 0.0001
Post-treatment change in U-β2M, serum ferritin and KL-6
- U-β2M decreased in survivors
- P = 0.009
- U-β2M increased in deceased patients
- P = 0.009
- Serum ferritin did not change significantly, survivors
- P = 0.086
- Serum ferritin did not change significantly, deceased
- P = 0.782
- KL-6 did not change significantly in survivors
- P = 0.059
- KL-6 increased in the deceased group
- P < 0.0001
Original publication
Urinary β2-microglobulin as a prognostic and treatment-associated biomarker in anti-MDA5 antibody-positive DM with interstitial lung disease. Rheumatology (Oxford). Published 13 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →